newsfilter
← Latest News
GlobeNewswire·

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

RNXT
  • RenovoRx published Phase III TIGeR-PaC sub-study PK/PD data in Cancer Chemotherapy and Pharmacology on August 25, 2026.
  • The study demonstrated approximately 51% local drug extraction of intra-arterial gemcitabine before systemic entry.
  • Intra-arterial delivery via the TAMP platform significantly reduced systemic gemcitabine exposure compared to intravenous delivery.
  • A statistically significant correlation was found between higher metabolite (dFdU) levels and reduced CA 19-9 tumor markers.
  • Enrollment for the TIGeR-PaC trial closed in August 2026 with 16 patients across six sites.
  • Trial completion is expected in the first half of 2027, with top-line data anticipated in the second half of 2027.
  • The study confirmed consistent pharmacokinetic delivery regardless of whether the superior mesenteric artery or celiac artery was used.
  • RenovoRx generated $909,000 in quarterly revenue in Q2 2026 from its commercialized RenovoCath device.
  • The IAG combination product candidate holds Orphan Drug Designation for pancreatic cancer.